DOCSLIB.ORG

Nanotechnology Enabled Regenerative Medicine for Neurological Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nanotechnology Enabled Regenerative Medicine for Neurological Disorders Advanced Drug Delivery Reviews 148 (2019) 1–2 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Nanotechnology enabled regenerative medicine for neurological disorders Tao L. Lowe a,⁎, Vivek Agrahari b, Rangaramanujam M. Kannan c, Sujatha Kannan d Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA CONRAD, Eastern Virginia Medical School, Arlington, VA 22209, USA Center for Nanomedicine, Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA Regenerative therapy has evolved significantly in recent years with endogenous regenerative pathways in the brain. The authors discuss promising approaches to restore function of diseased, damaged and nanotechnology-based approaches that target cellular and extracellular aged tissues and organs. It is a highly interdisciplinary field that has components to enhance neural regeneration while suppressing cellular been made possible by the intersection of recent advances in bioengi- and extracellular inhibitory mechanisms triggered by injury that could neering, stem cell biology and nanotechnology. Incorporation of nano- impair repair and plasticity in the brain. In the perspective review by technology may allow better control over physicochemical and the Ferriero group [2], the unique challenges in considering advanced biological properties of a biomaterial compared to conventional tech- regenerative therapies in the newborn brain are discussed. Newborn nologies. Nanotechnology applications to regenerative therapy have brains are immature and actively changing due to normal brain devel- all the potential to revolutionize tissue regeneration and repair, and ul- opment. Ferriero et al. discuss that regenerative strategies need to be timately personalized medicine. This theme issue of Advanced Drug De- tailored to the gestational age at injury for enabling appropriate devel- livery Review provides comprehensive and critical reviews of recent opment and growth. Although injury to the spinal cord remains devas- developments, future directions, and possible challenges in advancing tating, significant advances have been made in developing novel regenerative therapy for treating neurological disorders using nano- therapies for regeneration of the spinal cord in the last decade. Schmidt technology. This issue has covered the fabrication, characterization, im- et al. [3] provide a thorough insight on the fabrication of nanomaterials aging, and theranostic applications of nanotechnology-based systems in ranging from nanoparticles, nanofibers, nanotubes to quantum dots and central nervous system (CNS) including brain and spinal cord, eye and their therapeutic effects, especially targeting inhibitory environment, in peripheral nerve regeneration. It also reviews in detail the progress of spinal cord injury. They also highlight emerging technologies including nanotechnology in speeding up stem cell research and development optogenetics, immunotherapy and genome editing through CRISPR/ for regenerative neurological medicine. Furthermore, this theme issue Cas9 for spinal cord repair, where nanomaterials have synergistic roles discusses nanoneurotoxicity and hurdles in nanomedicine clinical to play. translation and strategies for pre-clinical evaluation of nanocarriers for Several preclinical studies focused on advanced regenerative thera- regeneration and repair in the nervous system. Nanomaterials as tools pies have shown promise, however, clinical translation of these still re- for understanding CNS disease pathology, neuroplasticity as a target mains challenging. Development of these therapies is expensive and for biomaterial-based therapies for stroke, nanotheranostics as a com- complex requiring close collaboration between researchers, physicians, bined diagnostic and therapeutic entity for personalized medicine in regulatory bodies and industry. Fatemi and group [4] provide a detailed neurological disorders, nanomaterials as gene delivery devices to repro- overview of the challenges involved in translating regenerative thera- gram cells for ocular regeneration, nanomaterials as immunomodula- pies from the lab to the clinic. Pandit et al. [5] present a comprehensive tors to restore healthy immune system for neuronal regeneration, and insight and design of histological, bio-imaging, molecular and behav- the use of zebrafish as a model for evaluating neuroregenerative thera- ioral modalities to screen brain-targeted nanosystems in pre-clinical peutics are some of the unique and promising topics featured in this models. Agrahari et al. [6] thoroughly review the effects of the composi- theme issue. tion of cell culture and biological matrices and nanoformulations’ phys- In general, regenerative therapies following injury can be considered icochemical properties on the in vivo performance of nanoformulations as either exogenous cell-based therapies to replace injured cells or en- for brain-targeted drug delivery. The authors also discuss the related an- dogenous strategies that enhance intrinsic regenerative capacities in alytical techniques under industrial settings to provide an enhanced un- the organ. The first article of this theme issue by S. Kannan and co- derstanding of the optimal design of brain-targeted nanoformulations workers [1] explores nanotechnology-based strategies to enhance for a successful clinical translation. Besides the comprehensive coverage of nanomaterials for develop- ⁎ Corresponding author. ing CNS therapies, this theme issue combines four papers by R. Kannan E-mail address: [email protected] (T.L. Lowe). et al. [7], Shoichet et al. [8], Yang et al. [9] and Song et al. [10] addressing https://doi.org/10.1016/j.addr.2019.11.006 0169-409X/© 2019 Published by Elsevier B.V. 2 the opportunities and challenges in leveraging the tremendous variety Finally, Mumm et al. [14] give a comprehensive review on the advan- of nanomaterials for understanding CNS disorders. It is important to rec- tages of zebrafish model in neuroregenerative imaging and therapeu- ognize that despite the common features between many CNS disorders, tics. They describe how zebrafish allow direct visualization of dynamic each presents a unique facet, and the nanoparticles must be tailored to cellular and molecular processes governing endogenous stem cell address the specific pathophysiology of a particular disorder. R. Kannan niche activities during regeneration. They also discuss how zebrafish and group [7] highlight how intrinsic association between dendrimers model can help to study the pharmacokinetics of nanocarriers and and disease pathology can be used for microglia-targeted therapies for screen nanoparticle-based drugs to find lead drugs that can promote en- neuroinflammation, producing promising neurobehavioral improve- hanced neuroregeneration. ments in multiple CNS models, an approach that is entering clinical tri- Together, this theme issue assembles cutting-edge articles from als for an unmet pediatric CNS disorder and beyond. Biomaterials can be leading experts in the field. We express our sincere gratitude to all au- vital tools enabling us to interact with brain cells and tissue, sensing thors who contributed to this timely and broadly informative theme their health and communicating it to a device, or using external stimuli issue of Advanced Drug Delivery Reviews. This special issue would not to manipulate brain cells to improve therapeutic outcomes. Shoichet have been possible without the critical evaluations by the reviewers et al. [8] identify factors and targets that influence post-stroke plasticity and the assistance provided by the journal editorial staff members to processes and discusses the role of biomaterials in enhancing the effi- ensure that the submissions are evaluated and published at high stan- cacy of treatment strategies for stroke. The manuscript by Yang et al. dards. Also, our sincere acknowledgement to Dr. Hamid Ghandehari, [9] provide a critical review of biodegradable materials that function Editor-in-Chief and Dr. María J. Vicent, Executive Editor of Advanced as electroactive, photoactive and magnetic materials facilitating man- Drug Delivery Reviews, for giving us the opportunity to develop this agement of neurological disorders. If biomaterials enable nerve regener- theme issue. We sincerely hope this theme issue will accelerate integra- ation in a safe manner, it would be a major advance in CNS disorders. In tive engagements in nanotechnology and regenerative medicine to a similar vein, Song and group [10] discuss how nanomaterials can en- move this exciting new field forward for revolutionary solutions to re- able improved functionality of stem cell therapies for CNS disorders. generate compromised, lost or damaged cells and tissues to treat neuro- For example, appropriately tailored nanoparticles can be tools for supe- logical disorders and improve the quality of life of patients in the future. rior directed differentiation, reprogramming, post-implant imaging, and drug delivery, addressing many challenges in stem cell therapies. References They outline the need for more in vivo studies for further translation. Furthermore, this theme issue includes extensive review by Gendelman [1] K. Liaw, Z. Zhang, S. Kannan, Neuronanotechnology for brain regeneration, Adv. et
Load more

Recommended publications
  • COVID-19 Publications - Week 05 2021 1328 Publications
    Update February 1 - February 7, 2021, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 05 2021 1328 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker Retracted papers AAN - Neurology resources COVID-19 risk tools - Apps COVID-19 resources (Harvard) Web app for SARS-CoV2 mutations COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With
    [Show full text]
  • Regenerative Medicine
    Growth Factors and Cellular Therapies in Clinical Musculoskeletal Medicine Douglas E. Hemler, M.D. STAR Spine & Sport Golden, CO June 13, 2016 Regenerative Medicine The term Regenerative Medicine was first coined in 1992 by Leland Kaiser1. Depending on the area of specialization, the definition varies. It is an evolving science that focuses on using components from our own bodies and external technologies to restore and rebuild our own tissues without surgery2. Closely related to Regenerative Medicine is a forward looking approach called Translational Medicine or Translational Science3. As applied to Musculoskeletal Regenerative Medicine, Translational Medicine is the application of scientific disciplines including tissue engineers, molecule biologists, researchers, industry and practicing clinicians who merge their science and experience to develop new approaches to healing tendons and joints. Some aspects of the field are highly complex, confined to laboratories and research institutions such as organ regeneration and embryonic stem cell research. Other areas are ready for clinical application. As defined by the European Society for Translational Medicine (EUSTM) it is an interdisciplinary branch of the biomedical field supported by three main pillars: bench side, bedside and community. The bench to bedside model includes transitioning clinical research to community practice using interactive science and data to benefit the community as a whole. Translational Medicine can be as complex as the research into total organ regeneration, total replacement of blood cell systems following cancer chemotherapy, or the scientific and ethical ramifications of embryonic stem cell research.45 Out of these efforts have come a group of therapies that are being applied by forward looking musculoskeletal practices such as STAR Spine and Sport.
    [Show full text]
  • Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes
    pharmaceutics Article Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes Franklin Afinjuomo 1, Thomas G. Barclay 1, Ankit Parikh 1, Yunmei Song 1, Rosa Chung 1, Lixin Wang 1, Liang Liu 1, John D. Hayball 1, Nikolai Petrovsky 2,3 and Sanjay Garg 1,* 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia; olumide.afi[email protected] (F.A.); [email protected] (T.G.B.); [email protected] (A.P.); [email protected] (Y.S.); [email protected] (R.C.); [email protected] (L.W.); [email protected] (L.L.); [email protected] (J.D.H.) 2 Vaxine Pty. Ltd., Adelaide, SA 5042, Australia; nikolai.petrovsky@flinders.edu.au 3 Department of Endocrinology, Flinders University, Adelaide, SA 5042, Australia * Correspondence: [email protected]; Tel.: +61-8-8302-1567 Received: 26 April 2019; Accepted: 16 May 2019; Published: 22 May 2019 Abstract: The propensity of monocytes to migrate into sites of mycobacterium tuberculosis (TB) infection and then become infected themselves makes them potential targets for delivery of drugs intracellularly to the tubercle bacilli reservoir. Conventional TB drugs are less effective because of poor intracellular delivery to this bacterial sanctuary. This study highlights the potential of using semicrystalline delta inulin particles that are readily internalised by monocytes for a monocyte-based drug delivery system. Pyrazinoic acid was successfully attached covalently to the delta inulin particles via a labile linker.
    [Show full text]
  • Advances in Nanomaterials in Biomedicine
    nanomaterials Editorial Advances in Nanomaterials in Biomedicine Elena Ryabchikova Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Science, 8 Lavrentiev Ave., 630090 Novosibirsk, Russia; [email protected] Keywords: nanotechnology; nanomedicine; biocompatible nanomaterials; diagnostics; nanocarriers; targeted drug delivery; tissue engineering Biomedicine is actively developing a methodological network that brings together biological research and its medical applications. Biomedicine, in fact, is at the front flank of the creation of the latest technologies for various fields in medicine, and, obviously, nanotechnologies occupy an important place at this flank. Based on the well-known breadth of the concept of “Biomedicine”, the boundaries of the Special Issue “Advances in Nanomaterials in Biomedicine” were not limited, and authors could present their work from various fields of nanotechnology, as well as new methods and nanomaterials intended for medical applications. This approach made it possible to make public not only specific developments, but also served as a kind of mirror reflecting the most active interest of researchers in a particular field of application of nanotechnology in biomedicine. The Special Issue brought together more than 110 authors from different countries, who submitted 11 original research articles and 7 reviews, and conveyed their vision of the problems of nanomaterials in biomedicine to the readers. A detailed and well-illustrated review on the main problems of nanomedicine in onco-immunotherapy was presented by Acebes-Fernández and co-authors [1]. It should be noted that the review is not limited to onco-immunotherapy, and gives a complete understanding of nanomedicine in general, which is useful for those new to this field.
    [Show full text]
  • The Future of Tissue Engineering and Regenerative Medicine in the African Continent
    Department of Biomedical Sciences Faculty of Science THE FUTURE OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE IN THE AFRICAN CONTINENT • DR KEOLEBOGILE MOTAUNG • TSHWANE UNIVERSITY OF TECHNOLOGY • DEPARTMENT OF BIOMEDICAL SCIENCES • TSHWANE • SOUTH AFRICA 1 Department of Biomedical Sciences Faculty of Science OUTLINE • Definition of TE and RM • Applications and Benefits • Research work • Challenges • Recommendations to improve gender content and social responsibility of research programmes in Africa that can enhance the effectiveness and sustainability of the development measures needed 2 Department of Biomedical Sciences Faculty of Science QUESTIONS ? How can one create human spare parts that has been damaged? Why do we have to create spare parts? 3 Department of Biomedical Sciences Faculty of Science HOW? TISSUE ENGINEERING AND REGENERATIVE MEDICINE • Is as science of design and manufacture of new tissues for the functional restoration of impaired organs and replacement of lost parts due to cancer, diseases and trauma. • Creation of human spare parts? 4 Department of Biomedical Sciences Faculty of Science WHY? DO WE HAVE TO CREATE HUMAN SPARE PARTS? • Shortage of donor tissues and organs • Survival rates for major organ transplantations are poor despite their high costs and the body's immune system often rejects donated tissue and organs. • Tissue engineering and Regenerative Medicine therefore, has remarkable potential in the medical field to solve these problems 5 Department of Biomedical Sciences Faculty of Science APPLICATIONS:
    [Show full text]
  • Regenerative Medicine Options for Chronic Musculoskeletal Conditions: a Review of the Literature Sean W
    Regenerative Medicine Options for Chronic Musculoskeletal Conditions: A Review of the Literature Sean W. Mulvaney, MD1; Paul Tortland, DO2; Brian Shiple, DO3; Kamisha Curtis, MPH4 1 Associate Professor of Medicine, Uniformed Services expected to be over 67 billion dollars in spending on University, Bethesda, MD biologics and cell therapies by 2020 (1). 2 FAOASM, Associate Clinical Professor of Medicine, University of Connecticut, Farmington, CT Specifically, regenerative medicine also stands 3 CAQSM, RMSK, ARDMS; The Center for Sports Medicine & in contrast to treatment modalities that impair Wellness, Glen Mills, PA the body’s ability to facilitate endogenous repair 4 Regenerative and Orthopedic Sports Medicine, Annapolis, MD mechanisms such as anti-inflammatory drugs (2,3); destructive modalities (e.g., radio frequency ablation of nerves, botulinum toxin injections) (4); Abstract and surgical methods that permanently alter the functioning of a joint, including joint fusion, spine egenerative medicine as applied to fixation, and partial or total arthroplasty. When musculoskeletal injuries is a term compared to other allopathic options (including knee used to describe a growing field of R and hip arthroplasty with a 90-day mortality rate of musculoskeletal medicine that concentrates 0.7% in the Western hemisphere) (5), regenerative on evidence-based treatments that focus on medicine treatment modalities have a lower and augment the body’s endogenous repair incidence of adverse events with a growing body of capabilities. These treatments are targeted statistically significant medical literature illustrating at the specific injury site or region of injury both their safety and efficacy (6). by the precise application of autologous, allogeneic or proliferative agents.
    [Show full text]
  • The Bridge Between Transplantation and Regenerative Medicine: Beginning a New Banff Classification of Tissue Engineering Pathology
    Received: 28 April 2017 | Revised: 21 November 2017 | Accepted: 24 November 2017 DOI: 10.1111/ajt.14610 PERSONAL VIEWPOINT The bridge between transplantation and regenerative medicine: Beginning a new Banff classification of tissue engineering pathology K. Solez1 | K. C. Fung1 | K. A. Saliba1 | V. L. C. Sheldon2 | A. Petrosyan3 | L. Perin3 | J. F. Burdick4 | W. H. Fissell5 | A. J. Demetris6 | L. D. Cornell7 1Department of Laboratory Medicine and Pathology, Faculty of Medicine and The science of regenerative medicine is arguably older than transplantation—the first Dentistry, University of Alberta, Edmonton, major textbook was published in 1901—and a major regenerative medicine meeting AB, Canada took place in 1988, three years before the first Banff transplant pathology meeting. 2Medical Anthropology Program, Department of Anthropology, Faculty of Arts and However, the subject of regenerative medicine/tissue engineering pathology has Sciences, University of Toronto, Toronto, never received focused attention. Defining and classifying tissue engineering pathol- Ontario, Canada ogy is long overdue. In the next decades, the field of transplantation will enlarge at 3Division of Urology GOFARR Laboratory for Organ Regenerative Research and least tenfold, through a hybrid of tissue engineering combined with existing ap- Cell Therapeutics, Children’s Hospital Los proaches to lessening the organ shortage. Gradually, transplantation pathologists will Angeles, Saban Research Institute, University of Southern California, Los Angeles, CA, USA become tissue- (re- ) engineering pathologists with enhanced skill sets to address con- 4Department of Surgery, Johns Hopkins cerns involving the use of bioengineered organs. We outline ways of categorizing ab- School of Medicine, Baltimore, MD, USA normalities in tissue- engineered organs through traditional light microscopy or other 5Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA modalities including biomarkers.
    [Show full text]
  • Introducing Bionanotechnology Into Undergraduate Biomedical Engineering
    AC 2009-504: INTRODUCING BIONANOTECHNOLOGY INTO UNDERGRADUATE BIOMEDICAL ENGINEERING Aura Gimm, Duke University J. Aura Gimm is Assistant Professor of the Practice and Associated Director of Undergraduate Studies in the Department of Biomedical Engineering at Duke University. She teaches courses in biomaterials, thermodynamics/kinetics, engineering design, and a new course in bionanotechnology. Dr. Gimm received her S.B. in Chemical Engineering and Biology from MIT, and her Ph.D. in Bioengineering from UC-Berkeley. Page 14.802.1 Page © American Society for Engineering Education, 2009 Introducing Bionanotechnology in Undergraduate Biomedical Engineering Abstract As a part of the NSF-funded Nanotechnology Undergraduate Education Program, we have developed and implemented a new upper division elective course in Biomedical Engineering titled “Introduction to Bionanotechnology Engineering”. The pilot course included five hands- on “Nanolab” modules that guided students through specific aspects of nanomaterials and engineering design in addition to lecture topics such as scaling effects, quantum effects, electrical/optical properties at nanoscale, self-assembly, nanostructures, nanofabrication, biomotors, biological designing, biosensors, etc. Students also interacted with researchers currently working in the areas of nanomedicine, self-assembly, tribiology, and nanobiomaterials to learn first-hand the engineering and design challenges. The course culminated with research or design proposals and oral presentations that addressed specific engineering/design issues facing nanobiotechnology and/or nanomedicine. The assessment also included an exam (only first offering), laboratory write-ups, reading of research journal articles and analysis, and an essay on ethical/societal implications of nanotechnology, and summative questionnaire. The course exposed students to cross-disciplinary intersections that occur between biomedical engineering, materials science, chemistry, physics, and biology when working at the nanoscale.
    [Show full text]
  • Nanotechnology in Regenerative Medicine: the Materials Side
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UPCommons. Portal del coneixement obert de la UPC Review Nanotechnology in regenerative medicine: the materials side Elisabeth Engel, Alexandra Michiardi, Melba Navarro, Damien Lacroix and Josep A. Planell Institute for Bioengineering of Catalonia (IBEC), Department of Materials Science, Technical University of Catalonia, CIBER BBN, Barcelona, Spain Regenerative medicine is an emerging multidisciplinary structures and materials with nanoscale features that can field that aims to restore, maintain or enhance tissues mimic the natural environment of cells, to promote certain and hence organ functions. Regeneration of tissues can functions, such as cell adhesion, cell mobility and cell be achieved by the combination of living cells, which will differentiation. provide biological functionality, and materials, which act Nanomaterials used in biomedical applications include as scaffolds to support cell proliferation. Mammalian nanoparticles for molecules delivery (drugs, growth fac- cells behave in vivo in response to the biological signals tors, DNA), nanofibres for tissue scaffolds, surface modifi- they receive from the surrounding environment, which is cations of implantable materials or nanodevices, such as structured by nanometre-scaled components. Therefore, biosensors. The combination of these elements within materials used in repairing the human body have to tissue engineering (TE) is an excellent example of the reproduce the correct signals that guide the cells great potential of nanotechnology applied to regenerative towards a desirable behaviour. Nanotechnology is not medicine. The ideal goal of regenerative medicine is the in only an excellent tool to produce material structures that vivo regeneration or, alternatively, the in vitro generation mimic the biological ones but also holds the promise of of a complex functional organ consisting of a scaffold made providing efficient delivery systems.
    [Show full text]
  • Cancer Nanomedicine: from Targeted Delivery to Combination Therapy
    Review Cancer nanomedicine: from targeted delivery to combination therapy 1,2,3 1 1 1,2 Xiaoyang Xu , William Ho , Xueqing Zhang , Nicolas Bertrand , and 1 Omid Farokhzad 1 Laboratory of Nanomedicine and Biomaterials, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA 2 The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA 3 Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA The advent of nanomedicine marks an unparalleled op- advantages of NPs have brought widespread attention to portunity to advance the treatment of various diseases, the field of nanomedicine, including their large ratio of including cancer. The unique properties of nanoparticles volume to surface area, modifiable external shell, biode- (NPs), such as large surface-to-volume ratio, small size, gradability, and low cytotoxicity [4]. Furthermore, nano- the ability to encapsulate various drugs, and tunable medicine brings us dramatically closer to realizing the full surface chemistry, give them many advantages over their promise of personalized medicine [5]. bulk counterparts. This includes multivalent surface mod- Engineered therapeutic NPs offer numerous clinical ification with targeting ligands, efficient navigation of the advantages. Surface modification with polyethylene glycol complex in vivo environment, increased intracellular traf- (PEG) protects NPs from clearance from the blood by the ficking, and sustained release of drug payload. These mononuclear phagocytic system (MPS), markedly increasing advantages make NPs a mode of treatment potentially both circulation times and drug uptake by target cells superior to conventional cancer therapies. This review [2,6].
    [Show full text]
  • COVID-19 Publications - Week 22 2020 709 Publications
    Update May 25 - May 31, 2020, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 22 2020 709 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker AAN - Neurology resources COVID-19 resources (Harvard) COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With Known or Suspected COVID-19 (ASA, 2020) OSHA Guidance on Preparing the Workplace for COVID-19 (2020) Policy for Sterilizers,
    [Show full text]
  • Personalized Nanomedicine
    Published OnlineFirst July 24, 2012; DOI: 10.1158/1078-0432.CCR-12-1414 Clinical Cancer Perspective Research Personalized Nanomedicine Twan Lammers1,2,3, Larissa Y. Rizzo1, Gert Storm2,3, and Fabian Kiessling1 Abstract Personalized medicine aims to individualize chemotherapeutic interventions on the basis of ex vivo and in vivo information on patient- and disease-specific characteristics. By noninvasively visualizing how well image-guided nanomedicines—that is, submicrometer-sized drug delivery systems containing both drugs and imaging agents within a single formulation, and designed to more specifically deliver drug molecules to pathologic sites—accumulate at the target site, patients likely to respond to nanomedicine-based therapeutic interventions may be preselected. In addition, by longitudinally monitoring how well patients respond to nanomedicine-based therapeutic interventions, drug doses and treatment protocols can be individualized and optimized during follow-up. Furthermore, noninvasive imaging information on the accumulation of nanomedicine formulations in potentially endangered healthy tissues may be used to exclude patients from further treatment. Consequently, combining noninvasive imaging with tumor-targeted drug delivery seems to hold significant potential for personalizing nanomedicine-based chemotherapeutic interventions, to achieve delivery of the right drug to the right location in the right patient at the right time. Clin Cancer Res; 18(18); 4889–94. Ó2012 AACR. Introduction Similarly, immunohistochemical tests evaluating the pro- Personalized medicine is often heralded as one of the tein expression levels of HER2, epidermal growth factor major leaps forward for 21st century medical practice (1). It receptor (EGFR), and c-kit in metastatic breast, colorectal, aims to individualize therapeutic interventions, incorpo- and gastrointestinal tumors, respectively, are approved by rating not only information obtained using ex vivo genetic the U.S.
    [Show full text]